Vision Shopsters: Biotech Success Rates 2003-2009
Vision Shopsters: Biotech Success Rates 2003-2009
The biotech industry is the driver of innovation in new treatment. Nevertheless, there is no clear data on the success rates of Biotech companies in drug development.
This report summarized the success rates of 211 publicly traded biotech companies with more than 1,500 drugs in development fort he period 2002 - 2009. The success rates are discussed per disease group and put into context to existing data on drug development attrition rates. The report also gives on outlook on the resulting implications for stakeholders of the biotech industry based on the identified drawbacks in the current biotech business model.
For more, kindly visit :http://www.visionshopsters.com/product/3363/Biotech-Success-Rates-2003-2009.html
Table Of Contents :
1 Introduction
1.1 Why a study on success rates of biotech companies?
1.2 What are success rates?
1.3 The role of success rates
1.4 Are success rates of biotech companies different?
2 Methods
2.1 Origin of Data
2.2 Difference between FDA and EMEA
2.3 Time frame
2.4 Success rates per molecule vs. success rates per indication
2.5 Companies of the sample
3 Results
3.1 Reporting of success and failure
3.2 Distribution of sample over disease groups
3.3 Overall biotech success rates (IND to approval)
3.4 Disease group specific overall success rates (IND to approval)
3.5 Number of projects in different disease groups
3.6 Disease group specific Success Rates
3.6.1 Cancer (471 projects)
3.6.2 Neurology (157 projects)
3.6.3 Infectious (56 projects)
3.6.4 Inflammation (127 projects)
3.6.5 Cardiovascular (85 projects)
3.6.6 Pain management (75 projects)
3.6.7 Dermatology (31 projects)
3.6.8 Endocrinology (27 projects)
3.6.9 Metabolic (66 projects)
3.6.10 Genitourinary (38 projects)
3.6.11 Hematology (28 projects)
3.6.12 Gastrointestinal (28 projects)
4 Discussion
4.1 Success Rates in Biotech (Avance) and Pharma (Kola, Landis)
4.2 Difference in cancer
4.3 Difference in Neurology
4.4 Difference in Infectious Diseases
4.5 Difference in Inflammation
4.6 Difference in Cardiovascula
4.7 Biotech has more late stage failures
4.8 Case Study: Arpida
4.9 Biotech does not abandon low potential drugs
5 Conclusion
For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3363/Biotech-Success-Rates-2003-2009.html
or email us your query at :info@visionshopsters.com
----------------------------------------------
Benficial Branded sumvision cyclone Better your life with laser vision correction Barry Lebowitz, Optometrist at Potomac Eye Care, Explains 20/20 Vision Vision Shopsters: US Smart Grid Roll-Out: Forging Ahead Locating the best practice for laser vision correction Do You Have a Vision For Your Life? Duke Peterson Vision Without Glasses Vision Without Glasses Free Improve Your Vision Without Glasses Don't Go Another Day Without Clear Vision Improve Vision Without Glasses LASIK plus vision center Ed Pill Effects On Vision